Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 13/20 | 0.48 |
| ▸ | CCNC | P24863 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | KMO | O15229 | 1/20 | 0.44 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | STK17B | O94768 | 1/20 | 0.41 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18918040 | 0.86 | BRD4 (0.50) | BRD4DYRK1ASTING1CNR2 | |
| SCHEMBL31294757 | 0.84 | GLS (0.55) | BRD4DYRK1ASTING1CNR2STK17B | |
| SCHEMBL31746641 | 0.83 | BRD4 (0.52) | BRD4STING1 | |
| SCHEMBL31746501 | 0.82 | BRD4 (0.51) | BRD4STING1 | |
| SCHEMBL31746582 | 0.82 | STING1 (0.55) | BRD4STING1CNR2 | |
| SCHEMBL24376372 | 0.80 | BRD4 (0.48) | BRD4KMOSTING1CNR2 | |
| SCHEMBL26910983 | 0.79 | BRD4 (0.47) | BRD4KMOSTING1CNR2 | |
| SCHEMBL16931162 | 0.78 | GLS (0.57) | BRD4KMO | |
| SCHEMBL18935520 | 0.76 | BRD4 (0.49) | BRD4CCNCCDK8DYRK1A | |
| SCHEMBL31130030 | 0.76 | BRD4 (0.39) | BRD4DYRK1AKMOSTING1STK17B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170158702-A1 | MULTIVALENT RAS BINDING COMPOUNDS | KYRAS THERAPEUTICS, INC. | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158702-A1 | MULTIVALENT RAS BINDING COMPOUNDS | KRAS, HRAS, NRAS | BRD4 359/4885CCNC 348/4885CDK8 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.